Literature DB >> 15475430

Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis.

Yoshihiro Yoshitake1, Tetsuya Nakatsura, Mikio Monji, Satoru Senju, Hidetake Matsuyoshi, Hirotake Tsukamoto, Seiji Hosaka, Hiroyuki Komori, Daiki Fukuma, Yoshiaki Ikuta, Toyomasa Katagiri, Yoichi Furukawa, Hiromi Ito, Masanori Shinohara, Yusuke Nakamura, Yasuharu Nishimura.   

Abstract

PURPOSE: To establish effective antitumor immunotherapy for esophageal cancer, we tried to identify an useful target antigen of esophageal cancer. EXPERIMENTAL
DESIGN: We did cDNA microarray analysis to find a novel candidate antigen, proliferation potential-related protein (PP-RP). We examined cytotoxicity against tumor cells in vitro and in vivo of CTLs specific to PP-RP established from esophageal cancer patients.
RESULTS: In 26 esophageal cancer tissues, an average of relative ratio of the expression of the PP-RP mRNA in cancer cells versus adjacent normal esophageal tissues was 396.2. Immunohistochemical analysis revealed that, in 20 of the 22 esophageal cancer tissues, PP-RP protein was strongly expressed only in the cancer cells and not so in normal esophageal epithelial cells. PP-RP protein contains 10 epitopes recognized by HLA-A24-restricted CTLs. These CTLs, generated from HLA-A24-positive esophageal cancer patients, had cytotoxic activity against cancer cell lines positive for both PP-RP and HLA-A24. Furthermore, adoptive transfer of the PP-RP-specific CTL line inhibited the growth of a human esophageal cancer cell line engrafted in nude mice.
CONCLUSIONS: The expression of PP-RP in esophageal cancer cells was significantly higher than in normal cells, and the CTLs recognizing PP-RP killed tumor cells in vitro and also showed tumor rejection effects in a xenograft model. Therefore, PP-RP may prove to be an ideal tumor antigen useful for diagnosis and immunotherapy for patients with esophageal cancer. cDNA microarray analysis is a useful method to identify ideal tumor-associated antigens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475430     DOI: 10.1158/1078-0432.CCR-04-0841

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  Expression analysis and association of RBBP6 with apoptosis in colon cancers.

Authors:  Zodwa Dlamini; Charleen Rupnarain; Sarala Naicker; Rodney Hull; Zukile Mbita
Journal:  J Mol Histol       Date:  2016-02-23       Impact factor: 2.611

2.  Systems genetics analyses predict a transcription role for P2P-R: molecular confirmation that P2P-R is a transcriptional co-repressor.

Authors:  Philippos Peidis; Thomas Giannakouros; Matthew E Burow; Robert W Williams; Robert E Scott
Journal:  BMC Syst Biol       Date:  2010-02-25

3.  De-regulation of the RBBP6 isoform 3/DWNN in human cancers.

Authors:  Zukile Mbita; Mervin Meyer; Amanda Skepu; Margot Hosie; Jasper Rees; Zodwa Dlamini
Journal:  Mol Cell Biochem       Date:  2011-12-03       Impact factor: 3.396

4.  Solution structure of RING finger-like domain of retinoblastoma-binding protein-6 (RBBP6) suggests it functions as a U-box.

Authors:  Mautin A Kappo; Eiso Ab; Faqeer Hassem; R Andrew Atkinson; Andrew Faro; Victor Muleya; Takalani Mulaudzi; John O Poole; Jean M McKenzie; Moredreck Chibi; Joanna C Moolman-Smook; D Jasper G Rees; David J R Pugh
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

5.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

6.  PACT is a negative regulator of p53 and essential for cell growth and embryonic development.

Authors:  Li Li; Binwei Deng; Guichun Xing; Yan Teng; Chunyan Tian; Xuan Cheng; Xiushan Yin; Juntao Yang; Xue Gao; Yunping Zhu; Qihong Sun; Lingqiang Zhang; Xiao Yang; Fuchu He
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

7.  Current gene expression studies in esophageal carcinoma.

Authors:  Wei Guo; Yao-Guang Jiang
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

8.  Overexpression of RBBP6, alone or combined with mutant TP53, is predictive of poor prognosis in colon cancer.

Authors:  Jian Chen; Huamei Tang; Zehua Wu; Chongzhi Zhou; Tao Jiang; Yingming Xue; Guoyu Huang; Dongwang Yan; Zhihai Peng
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

9.  Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma.

Authors:  Xiao-Li Du; Hai Hu; De-Chen Lin; Shu-Hua Xia; Xiao-Ming Shen; Yu Zhang; Man-Li Luo; Yan-Bin Feng; Yan Cai; Xin Xu; Ya-Ling Han; Qi-Min Zhan; Ming-Rong Wang
Journal:  J Mol Med (Berl)       Date:  2007-02-22       Impact factor: 5.606

10.  Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer.

Authors:  K Imai; S Hirata; A Irie; S Senju; Y Ikuta; K Yokomine; M Harao; M Inoue; Y Tomita; T Tsunoda; H Nakagawa; Y Nakamura; H Baba; Y Nishimura
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.